AGA Issues Guidance on Using P-CABs
Clinicians usually should not utilize potassium-competitive acid blockers (P-CAB) as first-line treatment for acid-related conditions, nonerosive gastroesophageal reflux illness (GERD), or peptic ulcer illness, according to a current medical practice upgrade from the American Gastroenterological Association (AGA).P-CABs are advised in location of proton pump inhibitors (PPIs) for many clients with Helicobacter pylori and other conditions where clients have not reacted to PPIs."P-CABs are a more recent medication class now readily available in the United States, connected with more quick, powerful, and extended stomach acid inhibition than PPI formulas," stated lead author Amit Patel, MD, a gastroenterologist at the Duke University School of Medicine and Durham Veterans Affairs Medical Cent...